| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1020270887 |
| P356 | DOI | 10.1186/1756-8722-6-30 |
| P953 | full work available online at | https://europepmc.org/articles/PMC3646677 |
| https://europepmc.org/articles/PMC3646677?pdf=render | ||
| https://jhoonline.biomedcentral.com/counter/pdf/10.1186/1756-8722-6-30 | ||
| https://link.springer.com/content/pdf/10.1186/1756-8722-6-30.pdf | ||
| P3181 | OpenCitations bibliographic resource ID | 1283680 |
| P932 | PMC publication ID | 3646677 |
| P698 | PubMed publication ID | 23617957 |
| P5875 | ResearchGate publication ID | 236337146 |
| P50 | author | Michael Karsy | Q96035296 |
| P2093 | author name string | Delong Liu | |
| Jian Zhuge | |||
| Tiangui Huang | |||
| Minghao Zhong | |||
| P2860 | cites work | The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner | Q21629049 |
| Back to the roots: the remarkable RAF oncogene story | Q24322964 | ||
| Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib | Q24594790 | ||
| BRAF mutations in hairy-cell leukemia | Q24609980 | ||
| Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation | Q24629474 | ||
| Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer | Q27851696 | ||
| Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. | Q27851801 | ||
| Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma | Q27851927 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Primary Structure of v- raf : Relatedness to the src Family of Oncogenes | Q28265918 | ||
| RAF protein-serine/threonine kinases: Structure and regulation | Q28289378 | ||
| Novel biomarkers for diagnosis, prognosis, targeted therapy and clinical trials | Q28680693 | ||
| Allele specific locked nucleic acid quantitative PCR (ASLNAqPCR): an accurate and cost-effective assay to diagnose and quantify KRAS and BRAF mutation | Q28730199 | ||
| BRAF mutation predicts sensitivity to MEK inhibition | Q29614281 | ||
| Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial | Q29614756 | ||
| Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K | Q29614757 | ||
| COT drives resistance to RAF inhibition through MAP kinase pathway reactivation | Q29615032 | ||
| RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF | Q29616828 | ||
| RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) | Q29620033 | ||
| BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. | Q30967043 | ||
| Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma | Q33384029 | ||
| From basic research to clinical development of MEK1/2 inhibitors for cancer therapy | Q33698374 | ||
| Targeting insulin-like growth factor axis in hepatocellular carcinoma | Q33951057 | ||
| MEK and the inhibitors: from bench to bedside | Q34036341 | ||
| The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma. | Q34101531 | ||
| High frequency of BRAF mutations in nevi | Q34160519 | ||
| Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation | Q53675468 | ||
| Detection of BRAF mutations in thyroid nodules by allele-specific PCR using a dual priming oligonucleotide system | Q54432201 | ||
| A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome | Q54516965 | ||
| Clinical implication of highly sensitive detection of the BRAF V600E mutation in fine-needle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4585 consecutive cases in a BRAF V600E mutation-prevalent area | Q54517500 | ||
| Mutation analysis of the BRAF codon 599 in malignant pleural mesothelioma by enriched PCR-RFLP. | Q54734458 | ||
| BRAF mutations in metastatic melanoma: a possible association with clinical outcome. | Q54756359 | ||
| BRAF mutations are associated with some histological types of papillary thyroid carcinoma | Q60527136 | ||
| BRAF Mutation in Papillary Thyroid Carcinoma | Q73276150 | ||
| Colorimetric approach to high-throughput mutation analysis | Q81732327 | ||
| BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas | Q34543110 | ||
| High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. | Q34559036 | ||
| BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer | Q34560988 | ||
| Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse | Q35022217 | ||
| BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing | Q35446668 | ||
| Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation | Q35876956 | ||
| CpG Island Methylation, Microsatellite Instability, and BRAF Mutations and Their Clinical Application in the Treatment of Colon Cancer. | Q36075933 | ||
| Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells | Q36556926 | ||
| Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis | Q36612290 | ||
| Synergistic Action of a RAF Inhibitor and a Dual PI3K/mTOR Inhibitor in Thyroid Cancer | Q36788057 | ||
| BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications | Q36972859 | ||
| RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors | Q37048053 | ||
| Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy | Q37286893 | ||
| Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response | Q37753517 | ||
| Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan | Q37771191 | ||
| Mutant BRAF Melanomas—Dependence and Resistance | Q37830845 | ||
| Role of BRAF in thyroid oncogenesis. | Q37928832 | ||
| Current management and novel agents for malignant melanoma | Q37983934 | ||
| BRAFmutation testing in clinical practice | Q37988572 | ||
| Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application | Q38164139 | ||
| Optimized allele-specific real-time PCR assays for the detection of common mutations in KRAS and BRAF. | Q38412630 | ||
| Diagnostic value of pyrosequencing for the BRAF V600E mutation in ultrasound-guided fine-needle aspiration biopsy samples of thyroid incidentalomas. | Q38501157 | ||
| Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation | Q39421033 | ||
| Vemurafenib and BRAF Inhibition: A New Class of Treatment for Metastatic Melanoma | Q39687000 | ||
| Braf(V600E) cooperates with Pten loss to induce metastatic melanoma | Q39873596 | ||
| Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. | Q39874679 | ||
| B-raf, a new member of the raf family, is activated by DNA rearrangement | Q40650163 | ||
| Sensitive detection of BRAF V600E mutation by Amplification Refractory Mutation System (ARMS)-PCR. | Q42176497 | ||
| JAK2V617F and p53 mutations coexist in erythroleukemia and megakaryoblastic leukemic cell lines | Q42386107 | ||
| BRAFV600E mutation and papillary thyroid cancer: chicken or egg? | Q42707282 | ||
| Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial | Q44442912 | ||
| A rapid and simple detection method for the BRAF(T1796A) mutation in fine-needle aspirated thyroid carcinoma cells | Q45239011 | ||
| The prevalence and prognostic value of BRAF mutation in thyroid cancer | Q46200580 | ||
| Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma | Q47573472 | ||
| A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma. | Q47650946 | ||
| Chromosomal assignment of two human B-raf(Rmil) proto-oncogene loci: B-raf-1 encoding the p94Braf/Rmil and B-raf-2, a processed pseudogene. | Q48162711 | ||
| P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | neoplasm | Q1216998 |
| dabrafenib | Q3011604 | ||
| protein kinase inhibitors | Q7251487 | ||
| B-Raf proto-oncogene, serine/threonine kinase | Q21109218 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 30 | |
| P577 | publication date | 2013-04-25 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Journal of Hematology & Oncology | Q15724593 |
| P1476 | title | B-Raf and the inhibitors: from bench to bedside | |
| P478 | volume | 6 |
| Q38640917 | ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development |
| Q38558611 | AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy |
| Q33884726 | Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma |
| Q38119931 | An overview on molecular biology of KIT/PDGFRA wild type (WT) gastrointestinal stromal tumours (GIST). |
| Q36273868 | Anti-inflammatory effects of dabrafenib in vitro and in vivo |
| Q26785828 | Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia |
| Q64055605 | Clinical development of targeted and immune based anti-cancer therapies |
| Q54325214 | Clinico-morphological features of BRAF inhibition-induced proliferative skin lesions in cancer patients. |
| Q58806326 | Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer |
| Q38748966 | Expression of Death Receptor 4 Is Positively Regulated by MEK/ERK/AP-1 Signaling and Suppressed upon MEK Inhibition |
| Q91713958 | Functionalized Graphene Oxide Thin Films for Anti-tumor Drug Delivery to Melanoma Cells |
| Q38578960 | Future of combination therapy with dabrafenib and trametinib in metastatic melanoma |
| Q58712149 | HS-1371, a novel kinase inhibitor of RIP3-mediated necroptosis |
| Q37113464 | Hairy cell leukemia in kidney transplantation: lesson from a rare disorder |
| Q45930485 | Histologic and immunohistochemical predictors of clinical behavior for feline diffuse iris melanoma. |
| Q38130010 | Ibrutinib and novel BTK inhibitors in clinical development |
| Q38888163 | Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing |
| Q35474544 | Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin β1/FAK signaling |
| Q58769992 | Is time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data |
| Q28548302 | Mitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant Transformation |
| Q38185477 | Neoadjuvant treatment of melanoma: case reports and review |
| Q38207082 | New RAF kinase inhibitors in cancer therapy |
| Q42222152 | Novel mechanisms of resistance to vemurafenib in melanoma - V600E B-Raf reversion and switching VEGF-A splice isoform expression |
| Q34037625 | Oncology Meets Immunology: The Cancer-Immunity Cycle |
| Q28833514 | Paradoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells |
| Q37350230 | Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. |
| Q38885822 | Preclinical analysis of the anti-tumor and anti-metastatic effects of Raf265 on colon cancer cells and CD26(+) cancer stem cells in colorectal carcinoma |
| Q42613711 | Programmed death 1 blockade, an Achilles heel for MMR-deficient tumors? |
| Q36416861 | Roles of palmitoylation and the KIKK membrane-targeting motif in leukemogenesis by oncogenic KRAS4A |
| Q38260357 | Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents |
| Q60548369 | Small molecule inhibition of RAS/MAPK signaling ameliorates developmental pathologies of Kabuki Syndrome |
| Q55279256 | Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy. |
| Q38585847 | Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy. |
| Q38975988 | Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma |
| Q38124821 | Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma |
| Q38397326 | The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy. |
| Q38559739 | The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma |
| Q91677833 | The impact of endothelial cell death in the brain and its role after stroke: A systematic review |
| Q39215892 | The plasma membrane Ca2+ pump PMCA4b inhibits the migratory and metastatic activity of BRAF mutant melanoma cells. |
| Q37515966 | Tyrosine kinase gene rearrangements in epithelial malignancies |
| Q40752102 | Unlocking the Potential of High-Throughput Drug Combination Assays Using Acoustic Dispensing |
| Q41852171 | Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer: a case report. |
| Q38357122 | Vemurafenib for the treatment of BRAF mutant metastatic melanoma |
Search more.